Clinical Trial Update: A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the safety and preliminary efficacy of a CD38 and CLL-1 dual-target CAR-T cell therapy for relapsed or refractory acute m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CAR-T cell therapy targeting CLL-1 and CD38

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING